DDInter946 DDInter1676
Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Interferon alfacon-1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Interferon alfacon-1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Interferon alfacon-1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Interferon alfacon-1 {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Interferon alfacon-1 {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Interferon alfacon-1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Baricitinib
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Aldesleukin